Literature DB >> 32440731

Effects of probiotic supplementation on serum trimethylamine-N-oxide level and gut microbiota composition in young males: a double-blinded randomized controlled trial.

Si Chen1,2, Ping-Ping Jiang1,2, Danxia Yu3, Gong-Cheng Liao1,2, Shang-Ling Wu1,2, Ai-Ping Fang1,2, Pei-Yan Chen1,2, Xiao-Yan Wang1,2, Yun Luo1,2, Jing-An Long1,2, Rong-Huan Zhong1,2, Zhao-Yan Liu1,2, Chun-Lei Li1,2, Dao-Ming Zhang1,2, Hui-Lian Zhu4,5.   

Abstract

PURPOSE: To explore whether probiotic supplementation could attenuate serum trimethylamine-N-oxide (TMAO) level and impact the intestinal microbiome composition.
DESIGN: Forty healthy males (20-25 years old) were randomized into the probiotic group (1.32 × 1011 CFU live bacteria including strains of Lactobacillus acidophilus, Lactobacillus rhamnosus GG, Bifidobacterium animalis, and Bifidobacterium longum daily) or the control group for 4 weeks. All participants underwent a phosphatidylcholine challenge test (PCCT) before and after the intervention. Serum TMAO and its precursors (TMA, choline and betaine) were measured by UPLC-MS/MS. The faecal microbiome was analyzed by 16S rRNA sequencing.
RESULTS: Serum TMAO and its precursors were markedly increased after the PCCT. No statistical differences were observed in the probiotic and the control group in area under the curve (AUC) (14.79 ± 0.97 μmol/L 8 h vs. 19.17 ± 2.55 μmol/L 8 h, P = 0.106) and the pre- to post-intervention AUC alterations (∆AUC) (- 6.33 ± 2.00 μmol/L 8 h vs. - 0.73 ± 3.04 μmol/L 8 h, P = 0.131) of TMAO; however, higher proportion of participants in probiotic group showed their TMAO decrease after the intervention (78.9% vs. 45.0%, P = 0.029). The abundance of Faecalibacterium prausnitzii (P = 0.043) and Prevotella (P = 0.001) in the probiotic group was significantly increased after the intervention but without obvious differences in α- and β-diversity.
CONCLUSIONS: The current probiotic supplementation resulted in detectable change of intestinal microbiome composition but failed to attenuate the serum TMAO elevation after PCCT. CLINICALTRIALS. GOV IDENTIFIER: NCT03292978. CLINICALTRIALS.GOV WEBSITE: https://clinicaltrials.gov/ct2/show/NCT03292978 .

Entities:  

Keywords:  Intestinal microbiome; Phosphatidylcholine challenge test; Probiotics; Randomized controlled trial; Trimethylamine-N-oxide (TMAO)

Mesh:

Substances:

Year:  2020        PMID: 32440731     DOI: 10.1007/s00394-020-02278-1

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  42 in total

1.  Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events.

Authors:  Richard B Kim; Bridget L Morse; Ognjenka Djurdjev; Mila Tang; Norman Muirhead; Brendan Barrett; Daniel T Holmes; Francois Madore; Catherine M Clase; Claudio Rigatto; Adeera Levin
Journal:  Kidney Int       Date:  2016-03-19       Impact factor: 10.612

2.  Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.

Authors:  W H Wilson Tang; Zeneng Wang; Bruce S Levison; Robert A Koeth; Earl B Britt; Xiaoming Fu; Yuping Wu; Stanley L Hazen
Journal:  N Engl J Med       Date:  2013-04-25       Impact factor: 91.245

3.  Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk.

Authors:  Weifei Zhu; Jill C Gregory; Elin Org; Jennifer A Buffa; Nilaksh Gupta; Zeneng Wang; Lin Li; Xiaoming Fu; Yuping Wu; Margarete Mehrabian; R Balfour Sartor; Thomas M McIntyre; Roy L Silverstein; W H Wilson Tang; Joseph A DiDonato; J Mark Brown; Aldons J Lusis; Stanley L Hazen
Journal:  Cell       Date:  2016-03-10       Impact factor: 41.582

4.  Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation.

Authors:  Brian J Bennett; Thomas Q de Aguiar Vallim; Zeneng Wang; Diana M Shih; Yonghong Meng; Jill Gregory; Hooman Allayee; Richard Lee; Mark Graham; Rosanne Crooke; Peter A Edwards; Stanley L Hazen; Aldons J Lusis
Journal:  Cell Metab       Date:  2013-01-08       Impact factor: 27.287

5.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.

Authors:  Zeneng Wang; Elizabeth Klipfell; Brian J Bennett; Robert Koeth; Bruce S Levison; Brandon Dugar; Ariel E Feldstein; Earl B Britt; Xiaoming Fu; Yoon-Mi Chung; Yuping Wu; Phil Schauer; Jonathan D Smith; Hooman Allayee; W H Wilson Tang; Joseph A DiDonato; Aldons J Lusis; Stanley L Hazen
Journal:  Nature       Date:  2011-04-07       Impact factor: 49.962

6.  Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study.

Authors:  Alison M Mondul; Steven C Moore; Stephanie J Weinstein; Edward D Karoly; Joshua N Sampson; Demetrius Albanes
Journal:  Int J Cancer       Date:  2015-05-09       Impact factor: 7.396

7.  Gut Microbiota-Dependent Trimethylamine-N-oxide and Serum Biomarkers in Patients with T2DM and Advanced CKD.

Authors:  Mohammed A I Al-Obaide; Ruchi Singh; Palika Datta; Kathy A Rewers-Felkins; Maria V Salguero; Ibtisam Al-Obaidi; Kameswara Rao Kottapalli; Tetyana L Vasylyeva
Journal:  J Clin Med       Date:  2017-09-19       Impact factor: 4.241

8.  Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults.

Authors:  Yu-ming Chen; Yan Liu; Rui-fen Zhou; Xiao-ling Chen; Cheng Wang; Xu-ying Tan; Li-jun Wang; Rui-dan Zheng; Hong-wei Zhang; Wen-hua Ling; Hui-lian Zhu
Journal:  Sci Rep       Date:  2016-01-08       Impact factor: 4.379

9.  Association of FMO3 Variants and Trimethylamine N-Oxide Concentration, Disease Progression, and Mortality in CKD Patients.

Authors:  Cassianne Robinson-Cohen; Richard Newitt; Danny D Shen; Allan E Rettie; Bryan R Kestenbaum; Jonathan Himmelfarb; Catherine K Yeung
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

Review 10.  Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease.

Authors:  Diede Fennema; Ian R Phillips; Elizabeth A Shephard
Journal:  Drug Metab Dispos       Date:  2016-05-17       Impact factor: 3.922

View more
  6 in total

Review 1.  Targeting Trimethylamine N-Oxide: A New Therapeutic Strategy for Alleviating Atherosclerosis.

Authors:  Lele Jing; Honghong Zhang; Qiannan Xiang; Liang Shen; Xiaoxia Guo; Changlin Zhai; Huilin Hu
Journal:  Front Cardiovasc Med       Date:  2022-06-13

Review 2.  Targets of statins intervention in LDL-C metabolism: Gut microbiota.

Authors:  ChangXin Sun; ZePing Wang; LanQing Hu; XiaoNan Zhang; JiYe Chen; ZongLiang Yu; LongTao Liu; Min Wu
Journal:  Front Cardiovasc Med       Date:  2022-09-08

Review 3.  Probiotics Bring New Hope for Atherosclerosis Prevention and Treatment.

Authors:  Taiyu Zhai; Pingping Wang; Xiumei Hu; Lei Zheng
Journal:  Oxid Med Cell Longev       Date:  2022-09-24       Impact factor: 7.310

4.  Bacterial Postbiotics as Promising Tools to Mitigate Cardiometabolic Diseases.

Authors:  Fernando F Anhê; Benjamin A H Jensen; Lais Rossi Perazza; André Tchernof; Jonathan D Schertzer; André Marette
Journal:  J Lipid Atheroscler       Date:  2021-02-09

Review 5.  Probiotics: A Dietary Factor to Modulate the Gut Microbiome, Host Immune System, and Gut-Brain Interaction.

Authors:  Tetsuji Hori; Kazunori Matsuda; Kenji Oishi
Journal:  Microorganisms       Date:  2020-09-11

6.  Molecular Identification and Selection of Probiotic Strains Able to Reduce the Serum TMAO Level in Mice Challenged with Choline.

Authors:  Latha Ramireddy; Hau-Yang Tsen; Yu-Chen Chiang; Chen-Ying Hung; Shih-Rong Wu; San-Land Young; Jin-Seng Lin; Chien-Hsun Huang; Shih-Hau Chiu; Chien-Chi Chen; Chih-Chieh Chen
Journal:  Foods       Date:  2021-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.